Pharmaceuticals News and Research

RSS

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Inergetics receives initial purchase order from New Marketlink for Resurgex Select

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a $112,500 purchase order for Resurgex Select from New Marketlink Pharmaceutical Corporation "New Marketlink."

2 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Explorys secures $2.55M Series B financing from Santé Ventures

Explorys Inc., the leader in cloud computing solutions for healthcare data management, analytics, and outcomes measurement has secured $2.55M Series B financing from Santé Ventures, with follow-on participation from Cleveland Clinic Innovations.

2 Aug 2010

K-V Pharmaceutical receives NYSE non-compliance notification

K-V Pharmaceutical Company announced today that the Company received notification from the New York Stock Exchange on July 27, 2010 of non-compliance regarding the Company's quantitative continued listing standards. The NYSE informed the Company that its Class A Common Stock equity issue has fallen below criteria for the average closing price of a NYSE security of not less than $1.00 over a consecutive 30-trading day period.

2 Aug 2010

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

Charles River Laboratories International, Inc. today reported its results for the second quarter of 2010. For the quarter, net sales were $292.1 million, a decline of 5.2% from $308.2 million in the second quarter of 2009. Foreign currency translation reduced the sales growth rate by 0.1%. A modest sales increase in the Research Models and Services segment was offset by lower sales for the Preclinical Services segment.

2 Aug 2010

INEOS agrees to sell Global Films business to Bilcare AG

INEOS Group has today entered into a binding agreement for the sale of its Global Films business to Bilcare AG, one of the world's leading providers of research led packaging to the global pharmaceuticals industry, for approximately EUR100 million. The agreement brings together complimentary capabilities and synergy's of two leading global businesses.

2 Aug 2010

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.

2 Aug 2010

GRS announces Martin as European General Manager, Executive Vice President of Global Development

Global Research Services, LLC (GRS), an international cardiovascular clinical research organization (CRO) serving pharmaceutical, biotech and medical device companies with comprehensive clinical trial management services, announced today that Benoît Martin, a seasoned executive with more than a decade of leading international CRO business units, has been named as the European General Manager and Executive Vice President of Global Development.

2 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

First regional student food drive to fight hunger

High schools throughout Southeastern Pennsylvania are invited to join Shire's The Great Food Fight!, the first regional student food drive to fight hunger. The goal: to collect 25 tons of food - the equivalent of 50,000 meals - for Philabundance and the thousands of local families who rely on the food services they provide. Shire will present the school that collects the most food per student a grand prize of $10,000.

31 Jul 2010

Perrigo files ANDA for butoconazole nitrate vaginal cream

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company, the owner of the New Drug Application as well as FemmePharma, the listed owner of the patent, of its ANDA filing. KV is a licensee under the patent. Perrigo believes it is first-to-file on this product.

31 Jul 2010

IQPC's Polymorphism & Crystallization Scientific Forum to address issues on polymorphs

There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC's Polymorphism & Crystallization Scientific Forum, taking place October 25- 27, 2010 in Philadelphia, PA will address these issues.

31 Jul 2010

Illinois quickly begins implementing new law to end violence in nursing homes; N.J. reverses cuts in AIDS drug program

Illinois Gov. Pat Quinn Thursday signed a law establishing new nursing home safety measures "aimed at ending chronic violence in the facilities. Work already has begun on hiring dozens of additional nursing home inspectors, as well as writing rules that will increase licensing fees and nursing staff levels in the homes. State authorities also say they are tackling one of the thorniest issues: finding ways to fund the law's multifaceted provisions even as Illinois faces a $13 billion budget deficit" (Jackson and Marx, 7/29).

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Angiotech reports $61.9 million total revenue for second-quarter 2010

Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Research establishes bases of possible future pharmaceutical drugs to combat AIDS virus

The doors are closing on the AIDS virus. The scientific community continues to strive to find the formula that will halt the advance of one of the viruses that has sparked most scientific interest over recent years. A study by the Consejo Superior de Investigaciones Cient-ficas (CSIC) and led by Mr F-lix Go-i, director of the Biophysics Unit at the CSIC-University of the Basque Country Mixed Centre, has developed a method of attack against the AIDS virus The method involves creating a prevention system, i.e. an 'armour' in the cells that are likely to be infected and thus impede, de facto, the virus from accessing them and starting to act on their immunological system.

31 Jul 2010

BioSpace launches 2010 BioMidwest Hotbed Campaign

BioSpace added Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies from Nebraska to Ohio.

31 Jul 2010

Laxai Pharma reaches agreement with UTA to extend terms of existing secured promissory note

Laxai Pharma Ltd., an international pharmaceutical contract research organization, recently reached an agreement with UTA Capital LLC to extend the terms of an existing secured promissory note issued by the Company in favor of UTA on March 3, 2010 in the aggregate principal amount of $1.44 million ("Note").

31 Jul 2010

Mylan prices $300 million aggregate principal amount of Senior Notes due 2020

Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.

31 Jul 2010

Pharmaceuticals News and Research

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Inergetics receives initial purchase order from New Marketlink for Resurgex Select

Xeomin receives FDA approval for treatment of cervical dystonia

Explorys secures $2.55M Series B financing from Santé Ventures

K-V Pharmaceutical receives NYSE non-compliance notification

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

INEOS agrees to sell Global Films business to Bilcare AG

Lexicon acquires equity shares of Symphony Icon Holdings

GRS announces Martin as European General Manager, Executive Vice President of Global Development

Merck reports strong bottom-line performance in second quarter

First regional student food drive to fight hunger

Perrigo files ANDA for butoconazole nitrate vaginal cream

IQPC's Polymorphism & Crystallization Scientific Forum to address issues on polymorphs

Illinois quickly begins implementing new law to end violence in nursing homes; N.J. reverses cuts in AIDS drug program

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Angiotech reports $61.9 million total revenue for second-quarter 2010

Research establishes bases of possible future pharmaceutical drugs to combat AIDS virus

BioSpace launches 2010 BioMidwest Hotbed Campaign

Laxai Pharma reaches agreement with UTA to extend terms of existing secured promissory note

Mylan prices $300 million aggregate principal amount of Senior Notes due 2020

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence